Overview Dividends

(DOCS) Doximity - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US26622P1075

Platform, Network, Collaboration, Telehealth, Recruitment

Health Care Technology
Market Cap in USD: 8,150m

IPO / Inception: 2021-06-24
Return 12m vs S&P 500: -29.3%

EPS (Earnings per Share)

EPS CAGR: -45.79%
EPS Trend: 40.2%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 15.59%
Rev. Trend: 92.8%

Last SUE: 2.30
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	54.6%
Value at Risk 5%th	70.1%
Relative Tail Risk	-21.96%

Reward TTM
Sharpe Ratio	-0.09
Alpha	-36.92
CAGR/Max DD	0.26

Character TTM
Hurst Exponent	0.551
Beta	1.238
Beta Downside	1.576

Drawdowns 3y
Max DD	49.92%
Mean DD	24.20%
Median DD	25.64%

Description: DOCS Doximity January 03, 2026

Doximity, Inc. (NYSE: DOCS) runs a U.S.-focused digital network for physicians, nurse practitioners, physician assistants, medical students, pharma firms, and health systems, offering tools for peer collaboration, news aggregation, career management, on-call scheduling, documentation, and virtual patient visits.

Founded in 2010 (originally 3MD Communications) and headquartered in San Francisco, the company sits in the Health Care Technology sub-industry and trades as common stock.

Key recent metrics: FY 2023 revenue topped $460 million, up ~30 % YoY, driven by a 20 % increase in advertising spend and a 15 % rise in subscription-based services; the platform now reaches roughly 84 % of U.S. physicians, giving it a highly defensible network effect.

Sector drivers include accelerating adoption of telehealth post-COVID-19, ongoing physician shortages that push clinicians toward efficiency-enhancing software, and rising health-system budgets for digital infrastructure, all of which support Doximity’s growth outlook.

For a deeper dive into Doximity’s valuation and risk profile, check the ValueRay analysis page.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (253.0m TTM) > 0 and > 6% of Revenue (6% = 37.3m TTM)

FCFTA 0.25 (>2.0%) and ΔFCFTA 5.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 153.2% (prev 159.7%; Δ -6.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.25 (>3.0%) and CFO 319.7m > Net Income 253.0m (YES >=105%, WARN >=100%)

Net Debt (-158.0m) to EBITDA (279.1m) ratio: -0.57 <= 3.0 (WARN <= 3.5)

Current Ratio 7.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (200.7m) change vs 12m ago 0.17% (target <= -2.0% for YES)

Gross Margin 90.20% (prev 89.94%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 52.31% (prev 46.21%; Δ 6.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -13.54 (EBITDA TTM 279.1m / Interest Expense TTM -19.6m) >= 6 (WARN >= 3)

Altman Z'' 7.92

(A) 0.76 = (Total Current Assets 1.09b - Total Current Liabilities 140.3m) / Total Assets 1.26b

(B) 0.13 = Retained Earnings (Balance) 157.7m / Total Assets 1.26b

(D) 0.99 = Book Value of Equity 159.4m / Total Liabilities 161.6m

Total Rating: 7.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 88.62

1. Piotroski 5.50pt

2. FCF Yield 4.32%

3. FCF Margin 50.61%

4. Debt/Equity 0.01

5. Debt/Ebitda -0.57

6. ROIC - WACC (= 10.75)%

7. RoE 23.90%

8. Rev. Trend 92.82%

9. EPS Trend 40.18%

What is the price of DOCS shares?

As of January 08, 2026, the stock is trading at USD 46.49 with a total of 2,369,808 shares traded.
Over the past week, the price has changed by +4.99%, over one month by +1.77%, over three months by -34.87% and over the past year by -16.20%.

Is DOCS a buy, sell or hold?

Doximity has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold DOCS.

Strong Buy: 5
Buy: 3
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DOCS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	67.9	46.1%
Analysts Target Price	67.9	46.1%
ValueRay Target Price	46.6	0.1%

DOCS Fundamental Data Overview January 04, 2026

Market Cap USD = 8.15b (8.15b USD * 1.0 USD.USD)
P/E Trailing = 34.632
P/E Forward = 26.6667
P/S = 13.1175
P/B = 7.6097
P/EG = 2.4191
Beta = 1.378
Revenue TTM = 621.3m USD
EBIT TTM = 265.7m USD
EBITDA TTM = 279.1m USD
Long Term Debt = 11.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.12m USD (from shortTermDebt, last quarter)
Debt = 11.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -158.0m USD (from netDebt column, last quarter)
Enterprise Value = 7.28b USD (8.15b + Debt 11.3m - CCE 878.4m)
Interest Coverage Ratio = -13.54 (Ebit TTM 265.7m / Interest Expense TTM -19.6m)
FCF Yield = 4.32% (FCF TTM 314.5m / Enterprise Value 7.28b)
FCF Margin = 50.61% (FCF TTM 314.5m / Revenue TTM 621.3m)
Net Margin = 40.72% (Net Income TTM 253.0m / Revenue TTM 621.3m)
Gross Margin = 90.20% ((Revenue TTM 621.3m - Cost of Revenue TTM 60.9m) / Revenue TTM)
Gross Margin QoQ = 90.25% (prev 89.18%)
Tobins Q-Ratio = 5.79 (Enterprise Value 7.28b / Total Assets 1.26b)
Interest Expense / Debt = 34.39% (Interest Expense 3.88m / Debt 11.3m)
Taxrate = 14.92% (10.9m / 72.9m)
NOPAT = 226.1m (EBIT 265.7m * (1 - 14.92%))
Current Ratio = 7.79 (Total Current Assets 1.09b / Total Current Liabilities 140.3m)
Debt / Equity = 0.01 (Debt 11.3m / totalStockholderEquity, last quarter 1.10b)
Debt / EBITDA = -0.57 (Net Debt -158.0m / EBITDA 279.1m)
Debt / FCF = -0.50 (Net Debt -158.0m / FCF TTM 314.5m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.13% (Net Income 253.0m / Total Assets 1.26b)
RoE = 23.90% (Net Income TTM 253.0m / Total Stockholder Equity 1.06b)
RoCE = 24.83% (EBIT 265.7m / Capital Employed (Equity 1.06b + L.T.Debt 11.3m))
RoIC = 21.35% (NOPAT 226.1m / Invested Capital 1.06b)
WACC = 10.61% (E(8.15b)/V(8.16b) * Re(10.58%) + D(11.3m)/V(8.16b) * Rd(34.39%) * (1-Tc(0.15)))
Discount Rate = 10.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.86%
[DCF Debug] Terminal Value 73.64% ; FCFE base≈275.6m ; Y1≈340.0m ; Y5≈580.2m
Fair Price DCF = 47.13 (DCF Value 6.47b / Shares Outstanding 137.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 40.18 | EPS CAGR: -45.79% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.82 | Revenue CAGR: 15.59% | SUE: 2.30 | # QB: 2
EPS current Year (2026-03-31): EPS=1.57 | Chg30d=+0.003 | Revisions Net=+1 | Growth EPS=+10.5% | Growth Revenue=+13.1%
EPS next Year (2027-03-31): EPS=1.72 | Chg30d=+0.007 | Revisions Net=+1 | Growth EPS=+9.8% | Growth Revenue=+11.1%

Additional Sources for DOCS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle